Current veterinary and equine program students eligible for scholarship and prizes.
ZetrOZ, Inc., manufacturer of the UltrOZ Elite low intensity therapeutic ultrasound, is pleased to announce its second annual essay contest, open to current veterinary and equine program students.
The author of the winning essay will receive a $1,000 scholarship; a school presentation from the UltrOZ Equine Division Manager, Brian Collins, and UltrOZ Consulting Veterinarian, Dr. Holly Schmitt; and have the opportunity for their essay to be published. Submissions are now being accepted and essays must be received no later than January 30, 2015.
Interested participants are encouraged to submit essays on the following topic:
As an equine professional, how do you advise your clients on the use of the variety of therapies currently available for treating, maintaining and even improving chronic injuries?
“We had a great response to our inaugural competition last year and are pleased to hold the essay contest again this year,” said Collins. “The quality of the essays we received last year was outstanding and it was difficult to pick a winner. We are really looking forward to seeing what students have to say in this year’s submissions.”
2015 UltrOZ Essay Contest Rules and Regulations:
1) Submissions should be a suggested length of 1,500 words.
2) Submissions must be received by 11:59 pm on January 30, 2015.
3) Submissions must be original and not infringe on the intellectual property rights of any third party.
4) Essays become the property of ZetrOZ, Inc. and ZetrOZ, Inc. retains the right to publish and/or redistribute any and all submissions. Appropriate citations will be given to the writers.
Danielle Stacy, winner of last year’s inaugural UltrOZ Essay Contest
Danielle Stacy, of Ipswich, MA, a third-year veterinary student at Cornell University, won UltrOZ’s first annual essay contest last year. She received a $1,000 scholarship. Stacy, whose course of study at Cornell has a focus in equine medicine, won the contest with her submission “Moving Towards a Clean Sport — The Role of Next Gen Therapies in Equine Sports Medicine.” Her essay also related to the role of Low Intensity Therapeutic Ultrasound in the field of equine sports medicine.
Essays should be submitted to [email protected] on or before January 30, 2015.
Complete Essay Contest details are available at http://www.ultroz.com/
About UltrOZ
UltrOZ Elite is the only wearable therapeutic ultrasound system for the maintenance and rehabilitation of equine athletes. UltrOZ Elite represents the next generation in safe and convenient ultrasound therapy that owners and riders can apply themselves, taking clinical therapy out of the doctor’s office and into the barn.
Ultrasound therapy has been used by veterinarians for decades, and by changing the way ultrasound is delivered, UltrOZ has eliminated the risk of thermal damage and created a safe and easy tool that promotes healing in tendon and ligament injuries; splints; muscles strain and tear; fracture and bone chip repair; minor strains, bumps, bruises, and inflammation. UltrOZ Elite also provides pain relief and can be used on a daily basis for maintenance.
UltrOZ Elite has been field tested by veterinarians and equine therapists, and is now being used extensively on the elite horse show circuits, racetracks, and training facilities to help keep equine athletes at the top of their game. World-class riders like McLain Ward (show jumping), Steffen Peters (dressage) and Tim McQuay (reining) are among those whose horses have benefited from UltrOZ Elite.
International show jumper Quentin Judge applying the UltrOZ Elite.
About ZetrOZ, Inc.
ZetrOZ, Inc. is an innovative ultrasound technology company focused on developing a new generation of ultrasound products and applications. Founded in Ithaca, NY in early 2009, ZetrOZ Inc. is now headquartered in Trumbull, CT. The Company’s technology was developed in collaboration with Cornell University, home of the world renowned Cornell Veterinary Hospital.
In 2014 ZetrOZ Inc. introduced sam (Sustained Acoustic Medicine) the first long-duration, wearable ultrasound device for treatment of chronic pain to be cleared by the FDA. The therapy has already gained wide acceptance among professional athletes and the company currently has a variety of clinical initiatives ongoing with the support of the National Institutes of Health, Department of Defense and NASA.
Further information about UltrOZ is available on line at www.UltrOZ.com. For more information about ZetrOZ, please visit www.ZetrOZ.com for information about sam (sustained acoustic medicine) www.samrecover.com.